Payment overview · 2025
General Payments
$919.25
42 reported records · 15 companies
Healthcare provider profile · identity verified
Jonathan Douglas Weaver, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SANTA MONICA, CA · NPI 1851318331
Verified facts
What the public records show
CMS Open Payments records show Jonathan Douglas Weaver, MD received $919.25 in general payments during 2025 across 42 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Linzess, Mounjaro, Ozempic, Tirosint.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
IBSA Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tirosint as an associated drug or biological on 6755 records involving 4085 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tirosint by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $186.28 | 20.3% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $122.84 | 13.4% | 5 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $93.96 | 10.2% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $84.97 | 9.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $83.80 | 9.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.72 | 6.2% | 3 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $52.86 | 5.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.05 | 4.8% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $43.96 | 4.8% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $32.07 | 3.5% | 1 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $30.44 | 3.3% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $25.02 | 2.7% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.50 | 2.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.16 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.62 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $919.25 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $84.97 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $83.59 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $75.38 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $75.38 | 3 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $72.49 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $55.03 | 3 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $52.86 | 3 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $52.86 | 3 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $52.86 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $47.46 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $44.05 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.86 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $32.07 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $30.44 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $28.77 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $28.77 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $25.02 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 71 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Tirosint tirosint |
2025 | Tirosint | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
141 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| IBSA Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | Tirosint open payments reported associated product |
CMS Open Payments — General Payments 6755 supporting records · 4085 recipient NPIs · example record 1211687357 |
Tirosint · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
71 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 399 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 240 | 58 |
| Gabapentin | Gabapentin | 212 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 203 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 167 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 158 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 151 | 36 |
| Synthroid | Levothyroxine Sodium | 141 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 38 |
| Eliquis | Apixaban | 134 | 19 |
| Losartan Potassium | Losartan Potassium | 129 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 32 |
| Lorazepam | Lorazepam | 122 | 31 |
| Trazodone Hcl | Trazodone Hcl | 108 | 24 |
| Allopurinol | Allopurinol | 84 | 25 |
| Clonazepam | Clonazepam | 81 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 26 |
| Alprazolam | Alprazolam | 79 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 15 |
| Mirtazapine | Mirtazapine | 76 | 19 |
| Azithromycin | Azithromycin | 75 | 59 |
| Eszopiclone | Eszopiclone | 75 | 15 |
| Sertraline Hcl | Sertraline Hcl | 75 | 17 |
| Simvastatin | Simvastatin | 72 | 18 |
| Mounjaro | Tirzepatide | 71 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 70 | 54 |
| Estradiol | Estradiol | 70 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 14 |
| Finasteride | Finasteride | 68 | 14 |
| Metformin Hcl | Metformin Hcl | 68 | 21 |
| Ezetimibe | Ezetimibe | 66 | 18 |
| Donepezil Hcl | Donepezil Hcl | 65 | 11 |
| Montelukast Sodium | Montelukast Sodium | 65 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 14 |
| Furosemide | Furosemide | 57 | 15 |
| Januvia | Sitagliptin Phosphate | 57 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 53 | 16 |
| Paxlovid | Nirmatrelvir/Ritonavir | 49 | 47 |
| Atenolol | Atenolol | 48 | 12 |
| Bupropion Xl | Bupropion Hcl | 46 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 39 |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Premarin | Estrogens, Conjugated | 42 | 11 |
| Ozempic | Semaglutide | 41 | suppressed |
| Diazepam | Diazepam | 40 | 11 |
| Famotidine | Famotidine | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 26 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 38 | suppressed |
| Pregabalin | Pregabalin | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | 12 |
| Levofloxacin | Levofloxacin | 35 | 22 |
| Lisinopril | Lisinopril | 35 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 22 |
| Valacyclovir | Valacyclovir Hcl | 32 | 23 |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Anastrozole | Anastrozole | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Carvedilol | Carvedilol | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 29 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 27 | suppressed |
| Testosterone | Testosterone | 27 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | 12 |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Cabergoline | Cabergoline | 23 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Nystatin | Nystatin | 22 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 16 |
| Omeprazole | Omeprazole | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 12 |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 11 |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 16 | 16 |
| Zaleplon | Zaleplon | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | suppressed |
| Modafinil | Modafinil | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Tadalafil | Tadalafil | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Dotti | Estradiol | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Tirosint | Levothyroxine Sodium | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $919.25 · 42 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AMVUTTRA, APLENZIN, APRETUDE, BREZTRI, CREON, Cleerly Labs, EVENITY, FARXIGA, Flector, GEMTESA, KISUNLA, LINZESS, Leqembi, Licart, MOUNJARO, Ozempic, Rybelsus, Saxenda, The Cologuard Plus Collection Kit, Tirosint, UBRELVY, WELLBUTRIN, Wegovy, XIFAXAN, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error